To compare the diagnostic accuracy and detection rates of PET/MRI with [68Ga]Ga-PSMA-11 and [68Ga]Ga-M2 in patients with biochemical recurrence of prostate cancer (PCa).
Sixty patients were enrolled in this prospective single-center phase II clinical trial from June 2020 to October 2022.